Harbour
The Independent Data Monitoring Committee (IDMC), upon review of the efficacy trend observed to date during the second interim analysis, recommended to Harbour BioMed (HBM) that further enrollment be ceased. However, the currently enrolled subjects will continue to be treated per protocol. No signals for serious safety concerns have been observed to date.
HBM will be following the IDMC recommendation. Once additional data from the remainder of the study becomes available, HBM then will further assess and determine the future plans related to the development of tanfanercept in
Phase 3 (study name: VELOS-3) in the US conducted by
Contact:
Tel: +82 1644-5515
Email: sales.info@hanall.co.kr
(C) 2022 Electronic News Publishing, source